Company Overview and News

38
Stitch Fix Stock Is Unravelling — Buy It While It’s Cheap!

2018-10-02 investorplace - 1
Stitch Fix (NASDAQ:SFIX) reported earnings last night and, after the initial knee-jerk spike, investors sold it down 30%-plus. SFIX delivered a decent report beating fourth-quarter expectations, but Wall Street hated the comments from management. Luckily for bulls, SFIX stock came into the earnings event up 80% year-to-date. This was even more of a gain than the almighty Amazon (NASDAQ:AMZN) could muster.
83GK AMZN 84GK SFIX

17
Applied Optoelectronics Stock Is a Falling Machete That’s Worth Catching

2018-09-27 investorplace - 5
Yesterday, the stock market moved on headlines from the U.S. Federal Reserve decision to raise rates. This morning, Applied Optoelectronics (NASDAQ:AAOI) is moving on its own set of headlines and it’s not looking good for AAOI stock.
83GK 84GK AAOI

4
Go Long the Apple September Event and Ignore the Rhetoric

2018-09-10 investorplace
Last week, the media coverage of the stock market made it sound like we were in the middle of a full-blown correction … yet when you look at the scoreboard, we are still near all-time highs. So I deem this a crisis of sentiment. Nothing has changed in the fundamentals, but it feels bearish.
83GK QQQ GOOGL 84GK AAPL GOOG

12
Buy Restoration Hardware Stock While the Market Hesistates

2018-09-05 investorplace
Restoration Hardware (NYSE:RH) reported earnings last night and Wall Street did not like what it saw. RH stock is down 5% this morning. This is the opposite reaction from Lululemon’s (NASDAQ:LULU) earnings event. These were both retail stocks that have been in favor with investors of late. But one down day for RH stock is not the end of its upside. And therein lies the opportunity.
83GK 84GK LULU RH

46
How to Trade Alibaba Stock After the Earnings Shock

2018-08-24 investorplace - 1
Alibaba (NYSE:BABA) stock has been on a long 20% slide since its June highs. This week, management reported earnings and the reaction was violent. First there was a negative knee-jerk dip to $170 per share in after-hours activity, but it reverted sharply higher.
83GK BABA AMZN 84GK

10
JD.com Stock Is Still Worth a Look Despite Tencent Earnings Miss

2018-08-17 investorplace
This year the U.S. stock market started a correction in early February from headline fears of rising rates. But since then, we have recovered nicely despite a slew of headline worries over global tariff wars. However the Chinese stock market continued this slide into a bear market territory. Stocks like JD.com (NASDAQ:JD) are still hideously caught up in the slide.
JD 83GK 84GK

8
Dropbox Stock Is Perfect for Those Who Ignore Wall Street’s Hate

2018-08-11 investorplace - 2
Last night, Dropbox (NASDAQ:DBX) reported earnings and there was after-hour jubilation but it died quickly. DBX stock is down 7.5% in early morning trading.
83GK DBX GOOGL 84GK AAPL GOOG

 
Google Alphabet restructuring reaches third anniversary

2018-08-10 cnbc
Three years ago Friday, Google co-founder and then-CEO Larry Page first announced the new corporate structure that separated Google's core businesses from its more experimental "Other Bets," including its health-care projects and venture capital arms.
83GK 84GK MS

12
There Is an Open House Sale on Zillow Stock

2018-08-08 investorplace
Zillow (NASDAQ:Z) stock had been lucky so far this year, up 36% year-to-date as of yesterday’s close. But last night management reported earnings and Wall Street hated what they saw.
83GK Z 84GK

 
Boeing Stock Can Still Fly Higher Despite Earnings Miss

2018-07-25 investorplace
So far, 2018 has been a year of headlines based on trade wars. Stock fundamentals are held hostage until these headlines abate, as there is tremendous uncertainty hanging in the balance and Wall Street doesn’t want to commit too far in either direction. Boeing (NYSE:BA) reported earnings this morning and the knee-jerk reaction is for traders to sell BA stock down roughly 3%.
83GK 84GK BA

40
The Rout In Netflix Stock Is a Gift for Bulls

2018-07-17 investorplace
Recently, the stock market has been on a roller coaster ride from the slew of global tariff headlines most notable against China. So far, Netflix (NASDAQ:NFLX) has been somewhat sheltered from it since China is not the heart of the growth thesis. Consequently, NFLX stock just recently set a record high and had been up 100% year-to-date. But that all changed last night when Reed Hastings & Co. reported earnings after hours and investors hated it.
83GK FB AMZN GOOGL 84GK NFLX NYTAB

2
WYNN Stock: The Recent Fall in Wynn Resorts Stock Is an Opportunity for Bulls | InvestorPlace

2018-07-10 investorplace
The stock market has been in whipsaw mode since the correction started in February. First we had traders reacting to a hotter-than-expected wage inflation report. But then the headline mode switched completely to rhetoric from the White House about trade wars with China and Europe.
83GK WYNN 84GK

51
TSLA Stock: Go Long Tesla Stock On Today’s Dip! | InvestorPlace

2018-07-06 investorplace - 2
Recently the stock market has been in turmoil due to the threats of global tariffs. Today we actually had the first wave of them imposed on $34 billion worth of Chinese imports into the U.S.
83GK 84GK TSLA

210
Go Long Netflix Stock Despite Trade War Uncertainty

2018-06-28 investorplace
This week has been volatile for stock prices. The White House escalated its rhetoric against China by threatening to limit Chinese Investments in the U.S. This is in addition to the already worrisome global tariff wars.
83GK FB 84GK AAPL NFLX DIS

113
Is Red Hat Stock a Falling Machete That’s Actually Worth Catching?

2018-06-22 investorplace - 1
Red Hat (NYSE:RHT) reported earnings last night and Wall Street absolutely hated what they saw and heard. The options markets were only expecting a +/-$8, yet the stock is falling $23-per-share on the headline.
83GK MU 84GK RHT CRM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...